Expertise in
2
conditions

Dr. Gil E. Harmon

Hematology
Gundersen Lutheran Medical Center Inc.
1900 South Ave, 
La Crosse, WI 
Accepting New Patients
Offers Telehealth
Expertise in
2
conditions
Gundersen Lutheran Medical Center Inc.
1900 South Ave, 
La Crosse, WI 

Overview

Gil Harmon is a Hematologist practicing medicine in La Crosse, Wisconsin.

Dr. Harmon is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Muscle Invasive Bladder Cancer, ALK-Positive Non-Small Cell Lung Cancer, and Gastroesophageal Junction Cancer.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 5 clinical trials. Dr. Harmon is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WI

Hospital Affiliations

Gundersen Moundview Hospital And Clinics
Gundersen St Josephs Hospital And Clinics
Gundersen Lutheran Medical Center
Tomah Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Gundersen Lutheran Medical Center Inc.
1900 South Ave, La Crosse, WI 54601

Additional Areas of Focus

Dr. Harmon has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
View 4 Less Clinical Trials

4 Total Publications

Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids.
Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids.
Journal: Frontiers in oncology
Published: January 10, 2024
Similar Doctors
Expertise in
51
conditions
Dr. Paula Gill
Hematology | Oncology
Expertise in
51
conditions
Dr. Paula Gill
Hematology | Oncology
Referral may be required

Mayo Clinic Health System In Lacrosse

700 West Ave S, 
La Crosse, WI 
 (0.7 miles away)
608-782-9760
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paula Gill is a Hematologist and an Oncologist practicing medicine in La Crosse, Wisconsin. Dr. Gill is highly rated in 51 conditions, according to our data. Her clinical expertise encompasses Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Gill is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Gundersen Lutheran Medical Center Inc

724 Denton St, 
La Crosse, WI 
 (0.1 miles away)
608-775-2385
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lori Rosenstein is a Hematologist practicing medicine in La Crosse, Wisconsin. Dr. Rosenstein is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, Thrombocytopenia, Adult Immune Thrombocytopenia, and Bone Marrow Aspiration. Dr. Rosenstein is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

Gundersen Lutheran Medical Center Inc.

1900 South Ave, 
La Crosse, WI 
 (0.1 miles away)
608-775-2385
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Wayne Bottner is a Hematologist practicing medicine in La Crosse, Wisconsin. Dr. Bottner is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Thrombotic Thrombocytopenic Purpura, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration. Dr. Bottner is currently accepting new patients.

Frequently Asked Questions about Dr. Gil E. Harmon

How do I make an appointment with Dr. Gil E. Harmon?

You can book an appointment with Dr. Gil E. Harmon by calling their office at 608-782-7300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gil E. Harmon a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gil E. Harmon is classified as an Advanced expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gil E. Harmon specialize in?

While Dr. Gil E. Harmon is a Hematology, they have specific expertise in Hodgkin Lymphoma, Muscle Invasive Bladder Cancer, and ALK-Positive Non-Small Cell Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Gil E. Harmon participate in research or clinical trials?

Yes. Dr. Gil E. Harmon has published 4 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Dr. Gil E. Harmon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gil E. Harmon accept my insurance?

Dr. Gil E. Harmon accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 608-782-7300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Harmon's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile